This is a working overview of thymalfasin, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-08-26. Anything still debated is marked as such rather than presented as settled.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
| Property | Value | Notes |
|---|---|---|
| Amino acid length | 28 residues | Single chain with an acetylated N-terminus |
| Molecular mass | Approximately 3,108 Da | Small shifts occur with counter-ion and water content |
| Isoelectric point | Around 3.5 | Low value follows from the many acidic residues |
| Parent molecule | N-terminal region of prothymosin alpha | Free circulating form in humans is not firmly established |
| Common synonyms | Thymalfasin; T alpha 1 | Older literature also uses the full spelled-out form |
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
2 CmF3 + F2 → 2 CmF4 A series of ternary fluorides are known of the form A7Cm6F31 (A = alkali metal). The colorless curium(III) chloride (CmCl3) is made by reacting curium hydroxide (Cm(OH)3) with anhydrous hydrogen chloride gas. It can be further turned into other halides such as curium(III) bromide (colorless to light green) and curium(III) iodide (colorless), by reacting it with the ammonia salt of the corresponding halide at temperatures of ~400–450 °C:
=== Logic === Formal logic is used for reasoning and knowledge representation. Formal logic comes in two main forms: propositional logic (which operates on statements that are true or false and uses logical connectives such as "and", "or", "not" and "implies") and predicate logic (which also operates on objects, predicates and relations and uses quantifiers such as "Every X is a Y" and "There are some Xs that are Ys"). Deductive reasoning in logic is the process of proving a new statement (conclusion) from other statements that are given and assumed to be true (the premises). Proofs can be structured as proof trees, in which nodes are labelled by sentences, and children nodes are connected to parent nodes by inference rules. Given a problem and a set of premises, problem-solving reduces to searching for a proof tree whose root node is labelled by a solution of the problem and whose leaf nodes are labelled by premises or axioms. In the case of Horn clauses, problem-solving search can be performed by reasoning forwards from the premises or backwards from the problem. In the more general case of the clausal form of first-order logic, resolution is a single, axiom-free rule of inference, in which a problem is solved by proving a contradiction from premises that include the negation of the problem to be solved. Inference in both Horn clause logic and first-order logic is undecidable, and therefore intractable. However, backward reasoning with Horn clauses, which underpins computation in the logic programming language Prolog, is Turing complete.
(2026). Iannucci et al. (2026) report the discovery of fossil material of a hyena belonging to the genus Crocuta from the Pirro III site (Italy), and interpret this finding as indicative of presence of Middle Pleistocene deposits at Pirro Nord. Khantemirov et al. (2026) study the morphology of teeth of late Pleistocene cave hyenas from the Tip-Tugai cave (Bashkortostan, Russia), and report differences in teeth morphology between Ural hyenas and most of the European ones which might be evidence of higher degree of adaptation to bone cracking in Ural hyenas. Evidence from the study of remains of the spotted hyena from the Pleistocene strata from the San Teodoro Cave (Sicily, Italy), indicative of slightly smaller body size of the spotted hyaenas from Sicily compared to their contemporaries from mainland Europe, is presented by Iurino et al. (2026). A nearly complete cranium of Adelphailurus kansensis, providing new information on the skull anatomy of members of this species, is described from the Hemphillian Big Sandy Formation (Arizona, United States) by Chatar & Tseng (2026). Salesa et al. (2026) study the functional anatomy of the hindlimbs of Promegantereon ogygia, and report evidence of morphological similarities to hindlimbs of the early felid Proailurus lemanensis. Evidence from the study of the neuroanatomy of Megantereon cultridens, interpreted as possibly indicative of scansorial adaptations, enhanced visual processing and preferences for closed environments, is presented by Meli et al. (2026).
Headgear called a "scrum cap" in rugby, or simply "headgear" or ear guard in wrestling and other martial arts, that protects the ears is worn to help prevent this condition. A specialty ear splint can also be made to keep the ear compressed, so that the damaged ear is unable to fill thus preventing cauliflower ear. For some athletes, however, a cauliflower ear is considered a badge of courage or experience.
== Further reading == Gregory, Kelvin B.; Bond, Daniel R.; Lovley, Derek R. (June 2004). "Graphite electrodes as electron donors for anaerobic respiration". Environmental Microbiology. 6 (6): 596–604. Bibcode:2004EnvMi...6..596G. doi:10.1111/j.1462-2920.2004.00593.x. ISSN 1462-2912. PMID 15142248.
Sources: en.wikipedia.org
Bacteria were first observed by the Dutch microscopist Antonie van Leeuwenhoek in 1676, using a single-lens microscope of his own design. Leeuwenhoek did not recognize bacteria as a distinct category of microorganisms, and referred to all microorganisms, including bacteria, protists, and microscopic animals, as animalcules. He published his observations in a series of letters to the Royal Society of London. His observations also included protozoans. The German Ferdinand Cohn began studying bacteria in 1870 and is also said to be a founder of bacteriology, as he was the first to classify bacteria into groups based on their cell shapes. He defined bacteria as "chlorophyll-free cells of spherical, oblong, or cylindrical form, sometimes twisted or bent, which multiply exclusively by transverse division and occur either isolated or in cell families," and placed them in the plant kingdom. He also discovered heat-resistant bacterial endospores Louis Pasteur demonstrated in 1859 that microorganisms cause the fermentation process, and that this growth is not due to spontaneous generation (yeasts and molds, commonly associated with fermentation, are not bacteria, but rather fungi). Along with his contemporary Robert Koch, Pasteur was an early advocate of the germ theory of disease. Between 1880 and 1881 Pasteur produced two successful vaccinations for animals against diseases caused by bacteria. The importance of bacteria was recognized as it led to a study of disease prevention and treatment of diseases by vaccines.
Wind direction plays a critical role in shaping the inland extent of X. parietina. Southwesterly winds in the warmer months carry marine aerosols further inland, while easterly storms contribute additional sea salt deposition through precipitation. The influence of these aerosols is evident in Maine cemeteries: X. parietina is more frequent in open cemeteries exposed to prevailing winds, compared to wooded cemeteries, which block or capture airborne sea salts, and have significantly lower frequencies of the lichen. In recent decades, inland populations of X. parietina have been discovered in southern Ontario, suggesting an expansion beyond its traditionally coastal range. Once considered extirpated from the region, the species was rediscovered growing on trees in several inland locations. This inland occurrence raises questions about whether the lichen has reestablished after a long absence or has persisted undetected for decades. The expansion may be linked to increasing nitrogen deposition from agricultural runoff and air pollution, which create conditions favorable for nitrophilous lichens like X. parietina. Another possible factor in its inland spread is the widespread use of road salt in Ontario over the past 50–70 years. Since X. parietina thrives in salt-rich coastal environments, roadside salt deposition may have provided an artificial habitat, mimicking the chemical conditions of maritime regions.
== Risks == The risks are similar to other intraocular procedures, but additionally include graft rejection (lifelong), detachment or displacement of lamellar transplants and primary graft failure. Use of immunosuppressants including cyclosporine A, tacrolimus, mycophenolate mofetil, sirolimus, and leflunomide to prevent graft rejection is increasing but there is insufficient evidence to ascertain which immunosuppressant is better. In a Cochrane review which included low to moderate quality evidence, adverse effects were found to be common with systemic mycophenolate mofetil, but less common with topical cyclosporine A or tacrolimus. There is also a risk of infection. Since the cornea has no blood vessels (it takes its nutrients from the aqueous humor) it heals much more slowly than a cut on the skin. While the wound is healing, it is possible that it might become infected by various microorganisms. This risk is minimized by antibiotic prophylaxis (using antibiotic eyedrops, even when no infection exists). There is a risk of cornea rejection, which occurs in about 10% of cases. Graft failure can occur at any time after the cornea has been transplanted, even years or decades later. The causes can vary, though it is usually due to new injury or illness. Treatment can be either medical or surgical, depending on the individual case. An early, technical cause of failure may be an excessively tight stitch cheesewiring through the sclera. Infectious disease transmission through corneal transplantation is exceedingly rare.
In organic chemistry, an amide, also known as an organic amide or a carboxamide, is a compound with the general formula R−C(=O)−NR′R″, where R, R', and R″ represent any group, typically organyl groups or hydrogen atoms. The amide functional group plays an important role in the chemistry of life where, as peptide bonds, they link amino acids together to form proteins. Amides can be viewed as a derivative of a carboxylic acid (R−C(=O)−OH) with the hydroxyl group (−OH) replaced by an amino group (−NR′R″); or, equivalently, an acyl (alkanoyl) group (R−C(=O)−) joined to an amino group. Common amides are formamide (H−C(=O)−NH2), acetamide (H3C−C(=O)−NH2), benzamide (C6H5−C(=O)−NH2), and dimethylformamide (H−C(=O)−N(−CH3)2). Amides are qualified as primary, secondary, and tertiary according to the number of acyl groups bounded to the nitrogen atom.
Sources: en.wikipedia.org
It is usually described as an immunomodulatory peptide rather than a classic circulating hormone. No endocrine gland is known to release it as a primary secretory product, and its measured presence in blood is not firmly established.
Prothymosin alpha is a much larger acidic protein, roughly 111 to 113 residues long, and the thymosin alpha-1 sequence matches its N-terminal region. The small peptide is therefore best understood as a fragment of that parent protein rather than a separate gene product.
Trials and clinical reports have examined chronic hepatitis B and C, use as a vaccine adjuvant, and supportive treatment in some immunodeficiency and oncology settings. Results vary by indication, and regulatory approval differs between countries.
It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.